Press Release Product Launch WHX Dubai 2026

Zoya Technologies Unveils ZoyeMed 3.0, an Edge-Native Autonomous AI Clinic, at WHX Dubai 2026

Zoya Technologies unveils ZoyeMed 3.0 — an edge-native autonomous AI clinic integrating real-time diagnostics, multimodal sensing, and longitudinal patient modelling for care delivery without cloud dependency.

WHX Dubai 2026
Published09 Feb 2026
Read Time2 min
Units Live44
Countries3
12L-ECG · LEAD II · ZoyeMed 3.0 EDGE-NATIVE AUTONOMOUS AI CLINIC · ZOYEMED 3.0 · WHX DUBAI 2026 SENSOR · SpO₂ · HR · BP
ZoyeMed 3.0 · Edge-Native Clinical Terminal
Autonomous Primary & Acute Care · On-Device AI
WHX Dubai 2026 · Press Release BusinessWire · Dubai, UAE · Feb 09, 2026

Zoya Technologies Unveils ZoyeMed 3.0, an Edge-Native Autonomous AI Clinic, at WHX Dubai

Zoya Technologies Unveils ZoyeMed 3.0, an Edge-Native
                    Autonomous AI Clinic, at WHX Dubai

Zoya Technologies has launched ZoyeMed 3.0, an edge-native clinical terminal engineered to provide autonomous primary and acute care with human oversight. Unveiled at WHX Dubai 2026, the system integrates on-device AI, multimodal sensing, point-of-care testing, and longitudinal patient modeling to enable high-precision diagnostics without depending on continuous cloud connectivity.

ZoyeMed 3.0 represents a significant architectural shift from earlier generations of ZoyeMed systems. While previous versions established a dense clinical sensorium, version 3.0 introduces a closed-loop, edge-first architecture that separates real-time safety and triage from higher-order reasoning, enabling longitudinal modeling over time. This approach allows care delivery to remain functional in environments with limited bandwidth, staffing constraints, or intermittent connectivity.

Since 2025, Zoya Technologies has shipped 44 ZoyeMed 1.0 units, with deployments underway in Mexico as part of a broader multi-phase contract covering up to 300 units. In Colombia, the company has signed agreements for 64 units per year over a three-year period. The first ZoyeMed 3.0 unit has already been delivered to Bogotá in preparation for pilot deployment following the WHX Dubai unveiling.

Unlike telemedicine platforms or AI copilots layered onto existing hospital systems, ZoyeMed 3.0 is designed as physical healthcare infrastructure, integrating diagnostics, decision support, and follow-up into a compact, on-site clinical unit. The system is intended to reduce cognitive load on clinicians while extending access to consistent, protocol-driven care at scale.

“ZoyeMed 3.0 moves clinical intelligence closer to the patient,” said Dr. Syed Sabahat Azim, Chief Executive Officer of Zoya Technologies. “By operating at the edge, the system is designed to function reliably even when connectivity is limited, while building a longitudinal view of patient health over time.”

Following the WHX Dubai unveiling, Zoya Technologies plans staged deployments of ZoyeMed 3.0 across Latin America, the Middle East, and South Asia.

About Zoya Technologies LLC

Zoya Technologies LLC is a deep-technology infrastructure company focused on building edge-native systems for real-world service delivery at scale. The company develops physically grounded, autonomous systems that integrate sensing, safety, and longitudinal intelligence, with healthcare as its first deployed domain.

Tags
Source & Attribution Originally distributed via BusinessWire, 9 February 2026. Technical documentation and PMCF data available to qualified reviewers — contact corporate@zoyel.one.
Share this article

Stay Updated

Get ZoyeMed updates directly.

Deployment milestones, clinical research releases, regulatory progress, and enterprise briefing invitations. No marketing noise - signal only.

Corporate email preferred. Unsubscribe any time. We do not share your data.

Enterprise Engagement

Ready to go deeper?

PMCF report, financial model, and IP technical disclosure are available to qualified institutional reviewers after a discovery call and NDA execution.

ZoyeMed® is a registered trademark of Zoya Technologies LLC. Class IIa Medical Device. CE Electrical · NYCE Mexico certified. CE-MDR, CDSCO, COFEPRIS, INVIMA in process. Longitudinal multimodal model architecture subject to PCT patent filing 2025-26. Technical disclosure available under NDA.
Link copied ✓